Key result
Parenchymal delivery of AAV5 in non-human primates resulted in robust transduction of neurons and astrocytes, with dose-dependent retrograde transport and extensive transduction of the corticospinal axis.
AAV5 parenchymal delivery in non-human primates demonstrates robust transduction and long-distance transport across the corticospinal axis, highlighting its potential for neurological gene therapy.
Supports AAV5 for corticospinal targeting in primate models; leaves open human translation and safety.
The present study was designed to characterize transduction of non-human primate brain and spinal cord with AAV5 viral vector after parenchymal delivery. AAV5-CAG-GFP (1 × 10 13 vector genomes per milliliter (vg ml −1 )) was bilaterally infused either into putamen, thalamus or with the combination left putamen and right thalamus. Robust expression of GFP was seen throughout infusion sites and also in other distal nuclei. Interestingly, thalamic infusion of AAV5 resulted in the transduction of the entire corticospinal axis, indicating transport of AAV5 over long distances. Regardless of site of injection, AAV5 transduced both neurons and astrocytes equally. Our data demonstrate that AAV5 is a very powerful vector for the central nervous system and has potential for treatment of a wide range of neurological pathologies with cortical, subcortical and/or spinal cord affection.
No takes yet. Share an insight, caveat, or question.
Samaranch et al. (2017) studied Neurological gene therapy delivery (n=3). AAV5-CAG-GFP was evaluated on Transduction and axonal transport of AAV5 viral vector in brain and spinal cord. Parenchymal delivery of AAV5 in non-human primates resulted in robust transduction of neurons and astrocytes, with dose-dependent retrograde transport and extensive transduction of the corticospinal axis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: